Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.

[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].

Niewerth M, Minden K, Klotsche J, Horneff G.

Z Rheumatol. 2014 Aug;73(6):532-40. doi: 10.1007/s00393-014-1378-z. German.

PMID:
25096586
[PubMed - in process]
2.

[Berlin transition program: from adolescents to adults in rheumatology treatment].

Minden K, Niewerth M, Müther S.

Z Rheumatol. 2014 Aug;73(6):526-31. doi: 10.1007/s00393-014-1377-0. German.

PMID:
25037479
[PubMed - in process]
3.

Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry.

Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.

Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.

PMID:
24942886
[PubMed - in process]
4.

Histomorphometry in antigen-induced arthritis of the rabbit temporomandibular joint.

Rafayelyan S, Radlanski RJ, Minden K, Pischon N, Jost-Brinkmann PG, Präger TM.

J Oral Pathol Med. 2014 Jun 16. doi: 10.1111/jop.12201. [Epub ahead of print]

PMID:
24935724
[PubMed - as supplied by publisher]
5.

A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis.

Benedetti FD, Rubio-Pérez N, Salazar CD, Goodman S, Job-Deslandre C, Joos R, Kone-Paut I, Minden K, Onel K, Porter-Brown B, Bharucha K, Wang J, Martini A, Lovell DJ, Brunner HI.

Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S67-8. doi: 10.1002/art.38461.

PMID:
24677974
[PubMed - in process]
6.

A38: Twelve Years' Experience with Etanercept in the Treatment of Juvenile Idiopathic Arthritis: How It Has Changed Practice-The German Biologics JIA Registry (BiKeR).

Schmeling H, Minden K, Foeldvari I, Haas JP, Hospach A, Horneff G.

Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S58. doi: 10.1002/art.38454.

PMID:
24677967
[PubMed - in process]
7.

A14: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis.

De Benedetti F, Ruperto N, Baildam E, Burgos-Vargas R, Horneff G, Huppertz HI, Minden K, Myones BL, Onel K, Wang J, Bharucha KN, Lovell DJ, Martini A, Brunner H.

Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S23-4. doi: 10.1002/art.38430.

PMID:
24677932
[PubMed - in process]
8.

A169: cumulative long-term safety, efficacy and patient-reported outcomes in children with juvenile idiopathic arthritis treated with intravenous abatacept: up to 7 years of treatment.

Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Magalhaes CS, Chavez-Corrales J, Huemer C, Kivitz AJ, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Deslandre C, Minden K, Block AJ, Giannini EH, Martini A.

Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S218-9. doi: 10.1002/art.38595.

PMID:
24677925
[PubMed - in process]
9.

Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.

Sengler C, Niewerth M, Kallinich T, Nimtz-Talaska A, Haller M, Huppertz HI, Minden K.

Clin Rheumatol. 2014 Jan;33(1):137-9. doi: 10.1007/s10067-013-2435-8. Epub 2013 Nov 28.

PMID:
24288046
[PubMed - in process]
10.

Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.

Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):253-62. doi: 10.1002/acr.22112.

PMID:
23983081
[PubMed - indexed for MEDLINE]
11.

[Transition of care from the perspective of pediatric rheumatology].

Minden K, Niewerth M.

Z Rheumatol. 2013 Oct;72(8):750-5. doi: 10.1007/s00393-013-1226-6. German. No abstract available.

PMID:
23872703
[PubMed - indexed for MEDLINE]
12.

Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors.

Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K.

Ocul Immunol Inflamm. 2013 Jun;21(3):180-91. doi: 10.3109/09273948.2013.791701. Review.

PMID:
23713827
[PubMed - indexed for MEDLINE]
13.

Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register.

Raab A, Sengler C, Niewerth M, Klotsche J, Horneff G, Zink A, Girschick H, Weber K, Minden K.

Clin Exp Rheumatol. 2013 Sep-Oct;31(5):796-802. Epub 2013 Apr 2.

PMID:
23557722
[PubMed - indexed for MEDLINE]
14.

[Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].

Minden K, Klotsche J, Niewerth M, Horneff G, Zink A.

Z Rheumatol. 2013 May;72(4):339-46. doi: 10.1007/s00393-012-1063-z. German.

PMID:
23456365
[PubMed - indexed for MEDLINE]
15.

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.

Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte M, Ganser G, Trauzeddel R, Huppertz HI.

Arthritis Res Ther. 2012 Oct 24;14(5):R230. doi: 10.1186/ar4072.

PMID:
23095307
[PubMed - in process]
Free PMC Article
16.

Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.

Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur-Zielinska H, Tauber T, Martini A, Foell D; Paediatric Rheumatology International Trials Organization (PRINTO).

Ann Rheum Dis. 2012 Dec;71(12):1991-7. doi: 10.1136/annrheumdis-2012-201329. Epub 2012 Jun 11.

PMID:
22689317
[PubMed - indexed for MEDLINE]
17.

Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.

Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G.

Rheumatology (Oxford). 2012 Aug;51(8):1407-15. doi: 10.1093/rheumatology/kes019. Epub 2012 Mar 24.

PMID:
22447885
[PubMed - indexed for MEDLINE]
Free Article
18.

Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood.

Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Graham E, Anton J, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich EC, Ramanan AV, Strand V; Multinational Interdisciplinary Working Group for Uveitis in Childhood.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1365-72. doi: 10.1002/acr.21674. Review.

PMID:
22438273
[PubMed - indexed for MEDLINE]
19.

Waiting for what? An inquiry into the fundamental questions of how to fix adolescent mental health care.

Minden K, Yamada S.

Healthc Q. 2011;14 Spec No 3:35-40.

PMID:
22008571
[PubMed - indexed for MEDLINE]
20.

Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, Baus H, Becker M, Bertram B, Dannecker G, Deuter C, Foeldvari I, Frosch M, Ganser G, Gaubitz M, Gerdes G, Horneff G, Illhardt A, Mackensen F, Minden K, Pleyer U, Schneider M, Wagner N, Zierhut M; German Ophthalmological Society; Society for Childhood and Adolescent Rheumatology; German Society for Rheumatology.

Rheumatol Int. 2012 May;32(5):1121-33. doi: 10.1007/s00296-011-2126-1. Epub 2011 Nov 15. Review.

PMID:
22083610
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk